Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLE
Bitget2026/09/23 11:05- Roivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
- Results have already been presented as topline data, showing the trial missed its main efficacy goal versus placebo.
- Secondary measures showed encouraging directional signals, particularly in patients with stronger biological responses.
- Development in cutaneous lupus will be halted, citing the overall readout and a competitive market backdrop.
- Safety was described as favorable, with other IMVT-1402 programs kept on their existing clinical timelines.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
